Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press19110.17650/1994-4098-2011-0-4-24-27MAMMOLOGY. PROBLEMМАММОЛОГИЯ. ПРОБЛЕМАThe specific features of T cell immunity in breast cancerОсобенности Т-клеточного иммунитета при раке молочной железыSkotarenkoL. V.СкотаренкоЛ. В.
Russian Federation
remrem84@mail.ruVorotnikovI. K.ВоротниковИ. К.
Russian Federation
KadagidzeZ. G.КадагидзеЗ. Г.
Russian Federation
ShamilovF. A.ШамиловФ. А.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ РОНЦ им. Н.Н. Блохина РАМН, Москва181120114242720082014200820142011https://ojrs.abvpress.ru/ojrs/article/view/191

The fact that the formation and growth of malignancies occur with pronounced immune impairments is beyond question now. In the past de- cades, great progress has been made in the studies of the immunology and immunotherapy of malignancies, including breast cancer. Despite intensive studies of the specific features of cell immunity in breast cancer, many points remain to be inadequately studied sofar and the avail- able information is controversial and scarce, which calls for further studies.

В настоящее время не вызывает сомнений тот факт, что формирование и рост злокачественных новообразований происходят на фоне выраженных нарушений иммунной системы. За последние десятилетия достигнуты большие успехи в исследовании иммунологии и иммунотерапии злокачественных опухолей, в том числе рака молочной железы. Несмотря на активное исследование особенностей клеточного иммунитета при раке молочной железы, многие детали пока остаются недостаточно изученными, а имеющаяся информация — спорной и немногочисленной, что и диктует необходимость дальнейшего изучения этой проблемы.

breast cancerantitumor immunityTreg cellsрак молочной железыпротивоопухолевый иммунитетTreg-клетки1. Seino K., Motohashi S., Fujisawa T. et al. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 2006;97:807–12.Seino K., Motohashi S., Fujisawa T. et al. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 2006;97:807–12.2. Tahir S.M., Cheng O., Shaulov A. et al. Loss of IFN-γ production by invariant NKT cells in advanced cancer. J Immunol 2001; 167:4046–50.Tahir S.M., Cheng O., Shaulov A. et al. Loss of IFN-γ production by invariant NKT cells in advanced cancer. J Immunol 2001; 167:4046–50.3. Itoh M., Takahashi T., Sakaguchi N. et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self- tolerance. J Immunol 1999;162:5317–26.Itoh M., Takahashi T., Sakaguchi N. et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self- tolerance. J Immunol 1999;162:5317–26.4. Fontenot J.D., Rudensky A.Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005;6:331–7.Fontenot J.D., Rudensky A.Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005;6:331–7.5. Sakaguchi S. The origin of FOXP3- expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest 2003;112:1310–2.Sakaguchi S. The origin of FOXP3- expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest 2003;112:1310–2.6. Juang C.M., Hung C.F., Yeh J.Y. Regulatory T cells: potential target in anticancer immunotherapy. Taiwan J Obstet Gynecol 2007;46(3):215–21.Juang C.M., Hung C.F., Yeh J.Y. Regulatory T cells: potential target in anticancer immunotherapy. Taiwan J Obstet Gynecol 2007;46(3):215–21.7. Ruter J., Barnett B.G., Kryczek I. et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci 2009;14:1761–70.Ruter J., Barnett B.G., Kryczek I. et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci 2009;14:1761–70.8. Azuma T., Takahashi T., Kunisato A. et al. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 2003;63:4516–20.Azuma T., Takahashi T., Kunisato A. et al. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 2003;63:4516–20.9. Lim H.W., Hillsamer P., Banham A.H. et al. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol 2005;175:4180–3.Lim H.W., Hillsamer P., Banham A.H. et al. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol 2005;175:4180–3.10. Trzonkowski P., Szmit E., Mysliwska J. et al. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004;112:258–67.Trzonkowski P., Szmit E., Mysliwska J. et al. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004;112:258–67.11. Romagnani C., Della Chiesa M., Kohler S. et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol 2005;35:2452–8.Romagnani C., Della Chiesa M., Kohler S. et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol 2005;35:2452–8.12. Chen W. Dendritic cells and (CD4+) CD25+ T regulatory cells: crosstalk between two professionals in immunity versus tolerance. Front Biosci 2006;11:1360–70.Chen W. Dendritic cells and (CD4+) CD25+ T regulatory cells: crosstalk between two professionals in immunity versus tolerance. Front Biosci 2006;11:1360–70.13. Wolf A.M., Wolf D., Steurer M. et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606–12.Wolf A.M., Wolf D., Steurer M. et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606–12.14. Liyanage U.K., Moore T.T, Joo H.G. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756–61.Liyanage U.K., Moore T.T, Joo H.G. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756–61.15. Mozaffari F., Lindemalm C., Choudhury A. et al. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer 2007;97:105–11.Mozaffari F., Lindemalm C., Choudhury A. et al. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer 2007;97:105–11.16. Okita R., Saeki T., Takashima S. et al. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005;14(5):1269–73.Okita R., Saeki T., Takashima S. et al. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005;14(5):1269–73.17. Abo-Elenein A., Elgohary S.E., Hashish A. et al. Significance of immunoregulatory T cells in different stages of breast cancer patients. Egypt J Immunol 2008;15(2):145–52.Abo-Elenein A., Elgohary S.E., Hashish A. et al. Significance of immunoregulatory T cells in different stages of breast cancer patients. Egypt J Immunol 2008;15(2):145–52.18. Курганова Е.В., Тихонова М.А., Ласкавая Е.Г. и др. Регуляторные Т-клетки при доброкачественныхКурганова Е.В., Тихонова М.А., Ласкавая Е.Г. и др. Регуляторные Т-клетки при доброкачественныхи злокачественных опухолях яичников. Иммунология 2009(6):349–55.19. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117(5):1167–74.Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117(5):1167–74.20. Baecher-Allan C., Anderson D.E. Immune regulation in tumorbearing hosts. Curr Opin Immunol 2006;18:214–9.Baecher-Allan C., Anderson D.E. Immune regulation in tumorbearing hosts. Curr Opin Immunol 2006;18:214–9.21. Leong P.P., Mohammad R., Ibrahim N. et al. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett 2006;102(2):229–36.Leong P.P., Mohammad R., Ibrahim N. et al. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett 2006;102(2):229–36.22. Ghebeh H., Barhoush E., Tulbah A. et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 2008; 8:57–68.Ghebeh H., Barhoush E., Tulbah A. et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 2008; 8:57–68.23. Bates G.J., Fox S.B., Han C. et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373–80.Bates G.J., Fox S.B., Han C. et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373–80.24. Polanczyk M.J., Carson B.D., Subramanian S. et al. Cutting edge: Estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 2004; 173:2227–30.Polanczyk M.J., Carson B.D., Subramanian S. et al. Cutting edge: Estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 2004; 173:2227–30.25. De Kruijf E.M., Van Nes J.G., Sajet A. et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 2010;16(4):1272–80.De Kruijf E.M., Van Nes J.G., Sajet A. et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 2010;16(4):1272–80.